Psychosis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：81頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Psychosis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Psychosis - Pipeline Review, H1 2014’, provides an overview of the Psychosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psychosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psychosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psychosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psychosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Psychosis - Pipeline Review, H1 2014’, provides an overview of the Psychosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psychosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psychosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psychosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psychosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Psychosis Overview 8
Therapeutics Development 9
Pipeline Products for Psychosis - Overview 9
Pipeline Products for Psychosis - Comparative Analysis 10
Psychosis - Therapeutics under Development by Companies 11
Psychosis - Therapeutics under Investigation by Universities/Institutes 13
Psychosis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Psychosis - Products under Development by Companies 18
Psychosis - Products under Investigation by Universities/Institutes 19
Psychosis - Companies Involved in Therapeutics Development 20
Eli Lilly and Company 20
Dainippon Sumitomo Pharma Co., Ltd. 21
H. Lundbeck A/S 22
Addex Therapeutics 23
Evotec AG 24
Acadia Pharmaceuticals Inc. 25
Newron Pharmaceuticals S.p.A. 26
Heptares Therapeutics Ltd. 27
Clera Inc. 28
Otsuka Holdings Co., Ltd. 29
Reviva Pharmaceuticals Inc. 30
Psychosis - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
zicronapine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pimavanserin tartrate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
aripiprazole - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pimavanserin tartrate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
oxytocin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
sodium benzoate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LY-404039 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule To Inhibit PDE10a For Central Nervous System - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NW-3509 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CLR-100 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ADX-71743 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drug Targeting Muscarinic M1/4 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Selective M1/M4 Muscarinic Acetylcholine Receptor Agonist - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VU-0092273 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CLR-136 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Sigma Receptor Agonists for CNS Disorders - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
RP-5063 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Psychosis - Recent Pipeline Updates 66
Psychosis - Dormant Projects 73
Psychosis - Discontinued Products 74
Psychosis - Product Development Milestones 75
Featured News & Press Releases 75
Nov 13, 2012: AstraZeneca Announces German Federal Patent Court Invalidates Seroquel XR Formulation Patent 75
Aug 30, 2012: Janssen Pharma To Pay $181m For Settlement Of Improper Marketing Claims For Antipsychotic Drugs 75
Apr 19, 2010: Mylan Launches Clozapine Tablets USP, 50mg And 200mg In US 76
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 76
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 77
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 78
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 78
Dec 19, 2003: Lundbeck Initiates Phase I Clinical Study Of Lu 31-130 For The Treatment Of Psychosis 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81
List of Tables
Number of Products under Development for Psychosis, H1 2014 9
Number of Products under Development for Psychosis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Comparative Analysis by Unknown Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Psychosis - Pipeline by Eli Lilly and Company, H1 2014 20
Psychosis - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 21
Psychosis - Pipeline by H. Lundbeck A/S, H1 2014 22
Psychosis - Pipeline by Addex Therapeutics, H1 2014 23
Psychosis - Pipeline by Evotec AG, H1 2014 24
Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 25
Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 26
Psychosis - Pipeline by Heptares Therapeutics Ltd., H1 2014 27
Psychosis - Pipeline by Clera Inc., H1 2014 28
Psychosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 29
Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 30
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Stage and Target, H1 2014 34
Number of Products by Stage and Mechanism of Action, H1 2014 37
Number of Products by Stage and Route of Administration, H1 2014 39
Number of Products by Stage and Molecule Type, H1 2014 41
Psychosis Therapeutics - Recent Pipeline Updates, H1 2014 66
Psychosis - Dormant Projects, H1 2014 73
Psychosis - Discontinued Products, H1 2014 74
List of Figures
Number of Products under Development for Psychosis, H1 2014 9
Number of Products under Development for Psychosis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Top 10 Target, H1 2014 32
Number of Products by Stage and Top 10 Target, H1 2014 33
Number of Products by Top 10 Mechanism of Action, H1 2014 35
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 36
Number of Products by Top 10 Route of Administration, H1 2014 38
Number of Products by Stage and Top 10 Route of Administration, H1 2014 39
Number of Products by Top 10 Molecule Type, H1 2014 40
Number of Products by Stage and Top 10 Molecule Type, H1 2014 41
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Psychosis Overview 8
Therapeutics Development 9
Pipeline Products for Psychosis - Overview 9
Pipeline Products for Psychosis - Comparative Analysis 10
Psychosis - Therapeutics under Development by Companies 11
Psychosis - Therapeutics under Investigation by Universities/Institutes 13
Psychosis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Psychosis - Products under Development by Companies 18
Psychosis - Products under Investigation by Universities/Institutes 19
Psychosis - Companies Involved in Therapeutics Development 20
Eli Lilly and Company 20
Dainippon Sumitomo Pharma Co., Ltd. 21
H. Lundbeck A/S 22
Addex Therapeutics 23
Evotec AG 24
Acadia Pharmaceuticals Inc. 25
Newron Pharmaceuticals S.p.A. 26
Heptares Therapeutics Ltd. 27
Clera Inc. 28
Otsuka Holdings Co., Ltd. 29
Reviva Pharmaceuticals Inc. 30
Psychosis - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
zicronapine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pimavanserin tartrate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
aripiprazole - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pimavanserin tartrate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
oxytocin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
sodium benzoate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LY-404039 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule To Inhibit PDE10a For Central Nervous System - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NW-3509 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CLR-100 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ADX-71743 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drug Targeting Muscarinic M1/4 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Selective M1/M4 Muscarinic Acetylcholine Receptor Agonist - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VU-0092273 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CLR-136 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Sigma Receptor Agonists for CNS Disorders - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
RP-5063 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Psychosis - Recent Pipeline Updates 66
Psychosis - Dormant Projects 73
Psychosis - Discontinued Products 74
Psychosis - Product Development Milestones 75
Featured News & Press Releases 75
Nov 13, 2012: AstraZeneca Announces German Federal Patent Court Invalidates Seroquel XR Formulation Patent 75
Aug 30, 2012: Janssen Pharma To Pay $181m For Settlement Of Improper Marketing Claims For Antipsychotic Drugs 75
Apr 19, 2010: Mylan Launches Clozapine Tablets USP, 50mg And 200mg In US 76
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 76
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 77
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 78
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 78
Dec 19, 2003: Lundbeck Initiates Phase I Clinical Study Of Lu 31-130 For The Treatment Of Psychosis 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81
List of Tables
Number of Products under Development for Psychosis, H1 2014 9
Number of Products under Development for Psychosis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Comparative Analysis by Unknown Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Psychosis - Pipeline by Eli Lilly and Company, H1 2014 20
Psychosis - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 21
Psychosis - Pipeline by H. Lundbeck A/S, H1 2014 22
Psychosis - Pipeline by Addex Therapeutics, H1 2014 23
Psychosis - Pipeline by Evotec AG, H1 2014 24
Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 25
Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 26
Psychosis - Pipeline by Heptares Therapeutics Ltd., H1 2014 27
Psychosis - Pipeline by Clera Inc., H1 2014 28
Psychosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 29
Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 30
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Stage and Target, H1 2014 34
Number of Products by Stage and Mechanism of Action, H1 2014 37
Number of Products by Stage and Route of Administration, H1 2014 39
Number of Products by Stage and Molecule Type, H1 2014 41
Psychosis Therapeutics - Recent Pipeline Updates, H1 2014 66
Psychosis - Dormant Projects, H1 2014 73
Psychosis - Discontinued Products, H1 2014 74
List of Figures
Number of Products under Development for Psychosis, H1 2014 9
Number of Products under Development for Psychosis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Top 10 Target, H1 2014 32
Number of Products by Stage and Top 10 Target, H1 2014 33
Number of Products by Top 10 Mechanism of Action, H1 2014 35
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 36
Number of Products by Top 10 Route of Administration, H1 2014 38
Number of Products by Stage and Top 10 Route of Administration, H1 2014 39
Number of Products by Top 10 Molecule Type, H1 2014 40
Number of Products by Stage and Top 10 Molecule Type, H1 2014 41
